ECOG STATISTICAL CENTER--DATA MANAGEMENT OFFICE

Summary

Principal Investigator: Robert Gray
Affiliation: Harvard University
Country: USA
Abstract: This office provides data management support for all ECOG studies, is responsible for registrations/randomizations, ADR reporting and reviews, and software development. The data Management Office at Frontier Science & Technology Research Foundation and the Statistical Office at the Dana Farber Cancer Institute together comprises the ECOG Statistical Center. The data management staff are involved in many aspects of ECOG activities and provide administrative and computing support for the Group.
Funding Period: 1994-08-05 - 2004-04-30
more information: NIH RePORT

Top Publications

  1. ncbi Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study
    Janice P Dutcher
    Our Lady of Mercy Cancer Center New York Medical College, Bronx, New York 10466, USA
    Cancer 104:2392-9. 2005
  2. ncbi Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282
    Minaxi Jhawer
    Department of Oncology, Montefiore Medical Center, Weiler Hospital, Room 2S 49, 1825 Eastchester Road, Bronx, NY 10461, USA
    Invest New Drugs 24:447-54. 2006
  3. pmc A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial
    Stacy Moulder
    Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1155 Pressler Street, Unit 1354, P O Box 301438, Houston, TX 77030, USA
    Breast Cancer Res Treat 119:663-71. 2010
  4. pmc Association of family history with cancer recurrence and survival among patients with stage III colon cancer
    Jennifer A Chan
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:2515-23. 2008
  5. pmc Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group
    David M Dilts
    Owen Graduate School of Management and Engineering Management Program, School of Engineering, Vanderbilt University, 401 21st Avenue South, Nashville, TN 37203, USA
    Clin Cancer Res 14:3427-33. 2008
  6. pmc Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group
    Robert Dreicer
    Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer 112:2671-5. 2008
  7. pmc Weekly paclitaxel in the adjuvant treatment of breast cancer
    Joseph A Sparano
    Eastern Cooperative Oncology Group, Philadelphia, USA
    N Engl J Med 358:1663-71. 2008
  8. doi A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study
    B A Burtness
    Department of Medical Oncology, Division of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Ann Oncol 19:977-83. 2008
  9. ncbi Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Kathy Miller
    Indiana University Cancer Center, Indianapolis, USA
    N Engl J Med 357:2666-76. 2007
  10. ncbi Flecainide for the treatment of chronic neuropathic pain: a Phase II trial
    Charles F Von Gunten
    Northwestern University, Chicago, Illinois, USA
    Palliat Med 21:667-72. 2007

Detail Information

Publications62

  1. ncbi Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study
    Janice P Dutcher
    Our Lady of Mercy Cancer Center New York Medical College, Bronx, New York 10466, USA
    Cancer 104:2392-9. 2005
    ..The current study evaluated the response rate and 6-month time to disease progression of the antiangiogenesis agent carboxyamidotriazole (CAI) in patients with metastatic renal cell carcinoma (RCC)...
  2. ncbi Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282
    Minaxi Jhawer
    Department of Oncology, Montefiore Medical Center, Weiler Hospital, Room 2S 49, 1825 Eastchester Road, Bronx, NY 10461, USA
    Invest New Drugs 24:447-54. 2006
    ..This regimen and sequence is worthy of further study especially in combination with colony stimulating factors, however, its tolerability may be most applicable for patients who have had minimal prior therapy...
  3. pmc A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial
    Stacy Moulder
    Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1155 Pressler Street, Unit 1354, P O Box 301438, Houston, TX 77030, USA
    Breast Cancer Res Treat 119:663-71. 2010
    ..Weekly ixabepilone and carboplatin plus trastuzumab have an acceptable toxicity profile, but are not likely to be associated with an RR of 75% in HER2+ MBC. Efficacy appears comparable to paclitaxel, carboplatin, and trastuzumab...
  4. pmc Association of family history with cancer recurrence and survival among patients with stage III colon cancer
    Jennifer A Chan
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:2515-23. 2008
    ..However, the influence of family history on cancer recurrence and survival among patients with established disease remains uncertain...
  5. pmc Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group
    David M Dilts
    Owen Graduate School of Management and Engineering Management Program, School of Engineering, Vanderbilt University, 401 21st Avenue South, Nashville, TN 37203, USA
    Clin Cancer Res 14:3427-33. 2008
    ..Calendar time was collected for each major process for each study in this set...
  6. pmc Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group
    Robert Dreicer
    Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer 112:2671-5. 2008
    ..A phase 2 trial of the combination of these 2 agents was performed in patients with advanced urothelial cancer who were previously untreated for metastatic disease...
  7. pmc Weekly paclitaxel in the adjuvant treatment of breast cancer
    Joseph A Sparano
    Eastern Cooperative Oncology Group, Philadelphia, USA
    N Engl J Med 358:1663-71. 2008
    ..We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer...
  8. doi A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study
    B A Burtness
    Department of Medical Oncology, Division of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Ann Oncol 19:977-83. 2008
    ..A high incidence of motor and sensory grade 3 neuropathy resulted at this dose and schedule. Further development of ixabepilone in previously treated head and neck cancer is not warranted on the basis of these data...
  9. ncbi Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Kathy Miller
    Indiana University Cancer Center, Indianapolis, USA
    N Engl J Med 357:2666-76. 2007
    ....
  10. ncbi Flecainide for the treatment of chronic neuropathic pain: a Phase II trial
    Charles F Von Gunten
    Northwestern University, Chicago, Illinois, USA
    Palliat Med 21:667-72. 2007
    ..Management of neuropathic pain is challenging. Medications that interfere with sodium channel transport, such as lidocaine, mexilitene and flecainide, are promising as analgesics...
  11. ncbi A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
    Kishan J Pandya
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    J Thorac Oncol 2:1036-41. 2007
    ..To study the progression-free survival (PFS) and toxicity with 25- or 250-mg doses of temsirolimus (CCI-779) after induction chemotherapy in patients with extensive small-cell lung cancer...
  12. pmc Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial
    H Ian Robins
    Department of Medicine, University of Wisconsin Cancer Center, CSC K4 5, 600 Highland Avenue, Madison, WI, 53792 616, USA
    Cancer Chemother Pharmacol 62:227-33. 2008
    ....
  13. ncbi Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group
    Robert Dreicer
    Department of Solid Tumor Oncology and the Urologic Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Cancer 110:759-63. 2007
    ..A phase 2 trial of this epothilone was performed to determine the activity and toxicity of this agent in a multi-institutional setting in patients previously treated with 1 prior chemotherapy regimen...
  14. ncbi Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794
    Gregory P Swanson
    Department of Radiation Oncology and Urology, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    J Clin Oncol 25:2225-9. 2007
    ..In this analysis, we stratified patients as to their preradiation PSA levels and correlated it with outcomes such as PSA treatment failure, local recurrence, and distant failure, to serve as guidelines for future research...
  15. ncbi Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    Bruce J Giantonio
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 25:1539-44. 2007
    ..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer...
  16. ncbi Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
    Ian W Flinn
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 25:793-8. 2007
    ..E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide (FC arm) versus fludarabine (F arm) alone in patients receiving their first chemotherapy regimen for CLL...
  17. pmc Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group
    Jeffrey M Ignatoff
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Urol Oncol 27:496-501. 2009
    ....
  18. pmc Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
    Lori J Goldstein
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:4092-9. 2008
    ..The purpose of this trial was to determine whether adjuvant AT improved disease-free survival compared with AC in operable breast cancer...
  19. pmc Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
    Lori J Goldstein
    Eastern Cooperative Oncology Group, Boston, MA, USA
    J Clin Oncol 26:4063-71. 2008
    ..Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than clinicopathologic features...
  20. ncbi Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up
    Peter H Wiernik
    Montefiore Medical Center North Division, Cancer Center, New York Medical College, Bronx, NY 10466, USA
    Leuk Lymphoma 50:1632-41. 2009
    ..002). Treatment toxicity was acceptable. After MOPP-Bleo induction for advanced Hodgkin lymphoma, ABVD provides better consolidation than local RT...
  21. pmc Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group
    Lorie L Hughes
    North Georgia RadiationTherapy The Hope Center, Cartersville 30121, USA
    J Clin Oncol 27:5319-24. 2009
    ..To determine the risk of ipsilateral breast events in patients with ductal carcinoma in situ (DCIS) treated with local excision without irradiation...
  22. doi Anthracycline dose intensification in acute myeloid leukemia
    Hugo F Fernandez
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    N Engl J Med 361:1249-59. 2009
    ..We evaluated the use of cytarabine plus either standard-dose or high-dose daunorubicin as induction therapy, followed by intensive consolidation therapy, in inducing complete remission to improve overall survival...
  23. pmc Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614
    Wayne M Koch
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Arch Otolaryngol Head Neck Surg 135:851-8. 2009
    ..To compare the results of clinical and pathological staging for a large cohort of patients with head and neck squamous cell carcinoma (HNSCC) and to examine patterns and ramifications of the disparity between staging methods...
  24. pmc Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer
    Robert Gray
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 27:4966-72. 2009
    ....
  25. pmc Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study
    Howard Hochster
    New York University Medical Center, New York, NY 10016, USA
    J Clin Oncol 27:1607-14. 2009
    ..To determine if maintenance rituximab (MR) after standard chemotherapy improves progression-free survival (PFS) in advanced-stage indolent lymphoma...
  26. doi The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 115:2155-64. 2009
    ....
  27. doi Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, United States
    Leuk Res 33:1485-9. 2009
    ..3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed...
  28. pmc A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, K6 568 CSC, 5669, 600 Highland Avenue, Madison, WI, 53792, USA
    Invest New Drugs 28:91-7. 2010
    ..The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC...
  29. pmc Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696
    John M Kirkwood
    Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 2584, USA
    Clin Cancer Res 15:1443-51. 2009
    ....
  30. pmc Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordin
    Michael B Atkins
    Beth Israel Deaconess Medical Center Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 26:5748-54. 2008
    ..In an effort to determine the relative efficacy of BCT compared with chemotherapy alone, a phase III trial was performed within the United States Intergroup...
  31. pmc The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794
    Gregory P Swanson
    University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    J Urol 180:2453-7; discussion 2458. 2008
    ..From the randomized study Southwest Oncology Group 8794 we evaluated the effect of seminal vesicle involvement on outcomes and whether those patients benefited from post-prostatectomy adjuvant radiation therapy...
  32. doi Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 72:108-13. 2008
    ..We performed a Phase I trial to test the safety and preliminary efficacy of adding oxaliplatin to standard preoperative chemoradiation therapy for rectal cancer...
  33. ncbi A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma
    Robert de W Marsh
    University of Florida, Department of Medicine, Division of Hematology Oncology, Gainesville, Florida 32610 0277, USA
    Am J Clin Oncol 30:26-31. 2007
    ..Perifosine, a heterocyclic alkylphosphocholine signal transduction inhibitor, has activity against multiple cell types in vitro. This is a phase II study to determine activity and toxicity of perifosine in pancreatic adenocarcinoma...
  34. ncbi Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599
    Corey Langer
    Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 25:418-23. 2007
    ..PS-2 patients on ECOG 1594 had a median survival (MS) of only 4.1 months and 1-year overall survival (OS) of 19%. Three percent had grade 5 toxicity...
  35. ncbi Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997
    Larry D Cripe
    Indiana University Medical Center, Indianapolis, IN, United States
    Leuk Res 30:823-7. 2006
    ..I. 27-30 days) and 25 days (95% C.I. 24-29 days), respectively. The trial does not confirm the high CR rate observed in phase II trials, despite optimal supportive care...
  36. ncbi Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:431-6. 2006
    ..To determine if thalidomide plus dexamethasone yields superior response rates compared with dexamethasone alone as induction therapy for newly diagnosed multiple myeloma...
  37. ncbi Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
    Mace L Rothenberg
    Division of Hematology Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
    J Clin Oncol 23:9265-74. 2005
    ..Serial serum samples were measured for amphiregulin and transforming growth factor-alpha (TGFalpha)...
  38. ncbi Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089
    Daniel G Haller
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 23:8671-8. 2005
    ..Intergroup (INT) 0089 assessed the relative contributions of leucovorin and levamisole in such patients...
  39. ncbi Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study
    Barbara Burtness
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
    J Clin Oncol 23:8646-54. 2005
    ..These cancers are rich in epidermal growth factor receptor (EGFR). We wished to determine whether the addition of cetuximab, which inhibits activation of EGFR, would improve PFS...
  40. ncbi Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Clin Breast Cancer 6:334-9. 2005
    ..The purpose of this multicenter phase II trial was to evaluate the clinical activity of topotecan as first-line chemotherapy in patients with metastatic breast cancer and previous exposure to adjuvant doxorubicin...
  41. ncbi Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)
    Nancy E Davidson
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 409, Baltimore, MD 21231, USA
    J Clin Oncol 23:5973-82. 2005
    ..Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established...
  42. ncbi Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281
    Weijing Sun
    University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    J Clin Oncol 23:4897-904. 2005
    ..Optimal treatments for metastatic carcinoid tumor remain undefined, and the role of chemotherapy for symptomatic patients with progressive disease is uncertain...
  43. ncbi A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497
    Int J Radiat Oncol Biol Phys 62:1345-50. 2005
    ..This randomized study was undertaken to determine whether the addition of 5-fluorouracil (5-FU) and mitomycin-C (MMC) to radiation therapy improves outcome in this patient population. Patients and..
  44. ncbi Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group
    Michael K Gibson
    Department of Medical Oncology, Sidney Kimmell Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    J Clin Oncol 23:3562-7. 2005
    ....
  45. ncbi Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience
    Kathleen J Yost
    Evanston Northwestern Healthcare Research Institute, USA
    Eval Health Prof 28:172-91. 2005
    ..MIDs for FACIT instruments established to date are summarized, and general guidelines that can be used to estimate MIDs for other FACIT instruments are provided. Applications of MIDs in research are illustrated...
  46. ncbi Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group
    C S Cleeland
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Oncol 16:972-80. 2005
    ..Cancer pain is highly prevalent and commonly undertreated. This study was designed to determine whether dissemination of a clinical protocol for pain management would improve outcomes in community oncology practices...
  47. ncbi Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group
    William R Friedenberg
    Department of Hematology Oncology, Guthrie Foundation for Education and Research, Sayre, Pennsylvania, USA
    Cancer 106:830-8. 2006
    ....
  48. pmc Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
    Jane N Winter
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Blood 107:4207-13. 2006
    ..Our finding that Bcl-6(+) cases did not benefit from the addition of R to CHOP requires independent confirmation...
  49. ncbi Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group
    Jill Gilbert
    Louisiana State University Medical Center, New Orleans, Louisiana, USA
    Head Neck 28:197-204. 2006
    ..The Eastern Cooperative Oncology Group (ECOG) initiated a phase II evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies...
  50. ncbi Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)
    Valerie W Rusch
    Thoracic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:313-8. 2007
    ..On the basis of improved outcomes in other subsets of stage III NSCLC, this trial tested the feasibility of induction chemoradiotherapy for SS NSCLC...
  51. ncbi Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:247-56. 2007
    ..Serum tumor marker decline during chemotherapy was assessed prospectively as a predictor of treatment outcome...
  52. ncbi Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Nashville, TN, USA
    N Engl J Med 355:2542-50. 2006
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers...
  53. ncbi The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
    Frederick R Appelbaum
    Southwest Oncology Group Statistical Center, Seattle, WA, USA
    Br J Haematol 135:165-73. 2006
    ..021), and in patients with t(8;21) (P = 0.025). OS was superior in patients who received regimens with high-dose cytarabine, a combination of fludarabine and intermediate-dose cytarabine, or haematopoietic cell transplantation...
  54. ncbi A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200
    B J Giantonio
    University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Oncol 17:1399-403. 2006
    ..Following a toxicity review of other trials using IFL, subsequent patients were enrolled at reduced doses of irinotecan (100 mg/m(2)) and 5-fluorouracil (400 mg/m(2))...
  55. ncbi A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia
    Mark R Litzow
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St S W, Rochester, MN 55905, USA
    Haematologica 91:1105-8. 2006
    ..One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL...
  56. ncbi Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study
    Brian I Rini
    Department of Medicine, University of California San Francisco Cancer Center, San Francisco, California, USA
    Biol Blood Marrow Transplant 12:778-85. 2006
    ..A graft-versus-tumor effect was not observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding of this approach. Allogeneic SCT remains investigational in RCC...
  57. ncbi Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
    Gregory Cairncross
    University of Calgary, Calgary, Alberta, Canada E mail
    J Clin Oncol 24:2707-14. 2006
    ..Furthermore, better outcomes in AO have been associated with 1p and 19q allelic loss...
  58. ncbi Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    Thomas M Habermann
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 24:3121-7. 2006
    ....
  59. ncbi Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy
    Edward M Messing
    Department of Urology, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Lancet Oncol 7:472-9. 2006
    ....
  60. ncbi Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196
    Stanley Zucker
    Veterans Affairs Medical Center, Northport, NY State University Hospital of New York, Stony Brook, USA
    Clin Breast Cancer 6:525-9. 2006
    ....
  61. pmc Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993
    Hillard M Lazarus
    Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA
    Blood 108:465-72. 2006
    ..03) for those without. CNS leukemia in adult ALL is uncommon at diagnosis. Adult Ph-negative ALL patients, however, can attain long-term disease-free survival using SCT as well as conventional chemotherapy...
  62. ncbi Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993)
    Janice P Dutcher
    Albert Einstein College NY, Bronx, NY, USA
    Leuk Lymphoma 46:377-85. 2005
    ..Combination therapy with other differentiating agents may be useful in this disease...